AI assistant
Dechra Pharmaceuticals PLC Director's Dealing 2021
4797_dirs_2021-10-06_f04518b8-6aa9-47cf-968d-41d5482d4e97.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 2548O
Dechra Pharmaceuticals PLC
06 October 2021
6 October 2021
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
Dechra Pharmaceuticals PLC announces that on 5 October 2021, Paul Sandland, Executive Director and PDMR exercised market value options over ordinary shares of 1p each in the Company. The options were granted under the Dechra Pharmaceuticals 2017 Long Term Incentive Plan as detailed below before Paul Sandland's appointment as an Executive Director. The exercise of the options was subject to the achievement of performance conditions which were satisfied to the extent that the options vested at 100%. Paul Sandland sold 3,960 of the shares acquired to fund the exercise prices and tax liabilities arising in connection with the exercises of the unapproved share options, and retained the remaining 2,040 shares.
| Date of Grant | Scheme | Number of options exercised | Option Price | Number of shares sold | Sale Price |
| 2 March 2018 | Approved | 550 | £25.06 | Nil | N/A |
| 2 March 2018 | Unapproved | 2,450 | £25.06 | 1,830 | £48.285 |
| 26 October 2018 | Unapproved | 3,000 | £21.66 | 2,130 | £48.285 |
Paul Sandland's total beneficial holding following these transactions is 9,651 ordinary shares which represents 0.009% of the total issued share capital.
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.
Notification of Dealing Forms
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Paul Sandland | |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/Chief Financial Officer | |
| b) | Initial notification/ amendment |
Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Exercise of options under the Company's 2017 Long Term Incentive Plan (Approved Options) | |
| c) | Price(s) and volumes(s) | Price(s) £25.06 |
Volume(s) 550 |
| d) | Aggregated information - Aggregate volume - Price - Total |
550 £25.06 £13,783.00 |
|
| e) | Date of the transaction | 2021.10.05 | |
| f) | Place of the transaction | Outside a trading venue |
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Paul Sandland | |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/Chief Financial Officer | |
| b) | Initial notification/ amendment |
Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Exercise of options under the Company's 2017 Long Term Incentive Plan (Unapproved Options) | |
| c) | Price(s) and volumes(s) | Price(s) £25.06 £21.66 |
Volume(s) 2,450 3,000 |
| d) | Aggregated information - Aggregate volume - Price - Total |
5,450 £23.188 £126,377.00 |
|
| e) | Date of the transaction | 2021.10.05 | |
| f) | Place of the transaction | Outside a trading venue |
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Paul Sandland | |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/Chief Financial Officer | |
| b) | Initial notification/ amendment |
Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Sale of shares obtained under the Company's 2017 Long Term Incentive Plan (Unapproved Options) | |
| c) | Price(s) and volumes(s) | Price(s) £48.285 |
Volume(s) 3,960 |
| d) | Aggregated information - Aggregate volume - Price - Total |
3,960 £48.285 £191,208.60 |
|
| e) | Date of the transaction | 2021.10.05 | |
| f) | Place of the transaction | London Stock Exchange |
For further information, please contact:
Melanie Hall, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBSBDGIXGDGBL